In Canada the five year survival rate for lung cancer is only at 15%. There is a great need to be able to detect the disease at an earlier stage which would lead to a better prognosis and outcome for the patient. Although many technologies and medical devices have been in use for standard procedure in the last decade, there are few which can detect lung lesions in the deeper portion, the periphery of the lung with reliability. The best option presently is called radial ultrasound, a device which focuses on tissue density but does not illuminate biochemical characteristics.
Better light collection by photodetectors would automatically improve signal to noise ratio and photodetector performance. For example, for the positron emission tomography application, it would result in a better image quality for a lower dose. The main cause of the light loss is too much reflection of light that is trying to travel from the light source into the semiconductor light sensor.
Chelation Partners Inc. has developed a family of new and highly selective iron chelators such as DIBI. In collaboration with Dr. Hoskin, DIBI is being investigated as a novel anti-cancer agent. Preliminary research suggests that DIBI can selectively inhibit the growth and survival of cancer cells and render them more sensitive to radiation therapy. The proposed research builds on previous work to increase our understanding of how the removal of iron by DIBI affects cancer cells and makes them more sensitive to radiation and/or chemotherapy.
Avertus Epilepsy Technologies Inc. is building a wireless headset that records brain waves (EEG) without requiring extensive, time-consuming and uncomfortable patient preparation. Avertus’ headset is a patient-focused, point-of care monitoring and detection system. To design the wireless EEG headset, commercially available dry electrodes will be analyzed and characterized to determine the optimum properties for better EEG recordings. A miniaturized circuit board will be designed for each electrode to make active electrodes that can provide a high quality EEG signal right on the headset.
Over 170 million persons worldwide are chronically infected by hepatitis C virus (HCV), leading to endstage liver disease and cancer. HCV is the single most common indication for liver transplantation in Canada and the rest of the Western world. After transplant, HCV re-infection is universal and is the chief cause of graft loss. Treatment of post-transplant recurrent HCV is more difficult than pretransplant, with lower response rates that partly reflect the effects of immunosuppression.We propose that the ideal management of post-transplant HCV is its prevention.
Epilepsy is a debilitating neurological disorder affecting approximately 50 million people worldwide (World Health Organization). This project proposes to develop a SMART (Seizure Monitoring At the Right Time) Headset for these patients to monitor their brain signal and track their movements, heart rates and breathing patterns. This headset will have new types of sensors suitable for long term usage and sleep.
The proposed project is two-phased. The first phase involves a study that will use specialized research analysis techniques to compare the effectiveness of pharmaceutical drugs used to treat type II diabetes and to identify if a group of drugs are producing similar benefits in terms of controlling the disease. The applicant’s clinical and epidemiological background would bring value to our study design for this and future projects. The second phase involves economic cost modeling that will forecast financial implications of study findings.
There is growing evidence that outcomes after colorectal surgery are improved with the use of perioperative interventions combined into an enhanced recovery program (ERP). Encouraging patients to achieve specific daily nutrition and mobilization goals postoperatively is an important aspect of ERPs; however, it is not known whether the achievement of these goals needs to be facilitated by a member of the healthcare team. This study aims to evaluate the extent to which postoperative recovery is influenced by facilitation of nutrition and mobility.
The goal of this research project is to explore the current definition of obesity along with the association of body fat distribution and biochemical markers with serious health conditions. Our investigation will employ the utilization of the dual-energy x-ray absorptiometry (the current gold standard to measure body fat percentage, subcutaneous body fat and visceral body fat) to more accurately define obesity and its association with cardiometabolic risk factors.
The proposed research project is a Phase 1 clinical trial looking at the safety of fenretinide, a molecule based on the structure of vitamin A, on patients with a disease called cystic fibrosis. Fenretinide has been shown in our laboratory to help cystic fibrosis mice by lowering molecules involved in inflammation and increasing the levels of docosahexaenoic acid (DHA), which is a fatty acid known to decrease inflammation. The intern will be involved in patient sample processing, analyzing and logging.